XtalPi (晶泰科技)

Shenzhen AI drug-discovery company founded on crystal-structure prediction — the first AI4S drug-discovery firm to list in Hong Kong.

1. Core Product / Service

XtalPi combines quantum physics, AI, and cloud automation to predict molecular structures and properties, anchored on its origin in crystal-structure prediction (CSP) — determining how a molecule packs into a crystal lattice, a step that is critical for drug solid-form selection. It has broadened into an "intelligent digital drug discovery" platform (ID4) spanning hit discovery through lead optimization, plus antibody discovery (XupremAb) and structure prediction (XtalFold) [local].

The other half of the business is robotic wet labs: XtalPi runs AI-driven autonomous labs that close the "design → execute → learn" loop, and also sells lab-automation solutions to outside customers. In its 2026 interim presentation it regrouped the business into drug-discovery solutions and AI4S intelligent solutions, with the robotic lab framed as the shared infrastructure and the company repositioned as an "open scientific-intelligence infrastructure platform" [local][gelonghui 2026-10-12].

Lab scale (per its listing prospectus): 200+ robotic workstations with a company-estimated peak throughput of ~1,500 experiments per day; >10,000 m² of lab space, of which >4,500 m² is robotic-workstation area. All premises are leased — 17 sites totalling ~37,200 m², including a ~11,200 m² Shenzhen HQ and a ~15,500 m² Shanghai lab, plus a robotic lab in Somerville, MA [local].

2. Target Users & Pain Points

• Pharma and biotech — the company reports serving 17 of the top-20 global pharma companies, including Pfizer, Eli Lilly, Roche, J&J/Janssen, Merck and Bayer [local] — needing solid-form screening, polymorphism prediction, and AI-assisted drug R&D.
• Pain solved: experimental crystal-form screening is slow and material-hungry; CSP shifts it to computation, and downstream AI tooling compresses discovery timelines.

3. Competitive Landscape

4. Unique Observations

• CSP as a wedge: crystal-structure prediction is a niche where physics-based accuracy is verifiable in the lab, giving XtalPi a defensible early moat before it broadened into full drug discovery.

• Pfizer validation: XtalPi's early high-profile collaboration was with Pfizer on crystal-form prediction — an early external validation of its physics+AI approach [local].

• China AI4S capital-market benchmark: as the most prominent listed Chinese AI4S drug-discovery company, XtalPi is the public-market reference point for the sector's "platform revenue real, blockbuster drug still absent" reality [local].

• AI-CRO vs full-service CRO (analysis): compared with WuXi AppTec by customer type and revenue mix, XtalPi competes as a differentiated AI-driven design layer (services-skewed revenue) rather than a full-stack chemistry/biology CRO, the same "new AI-native CRO vs incumbent" split seen elsewhere in the AI-bio stack [local].

• Capital, not operations, is the edge (Oct 2026): compared with domestic lab-automation peers (megarobo, 奔曜/Benyao, 玄刃/Xuanren), XtalPi looks stronger mainly because it has a public-market funding channel; stripping out one-off licensing income, its operating loss is in the same range as MegaRobo's [local].

• Clients may become competitors: top AI-drug companies such as insilico-medicine build their own robotic labs, which caps how much "lab-as-a-product" revenue integrators can capture — XtalPi hedges by keeping the lab in-house and selling results.

5. Financials / Funding

• Pre-IPO: eight private rounds totalling US$732M — reported as the largest pre-IPO total among AI drug-discovery companies; e.g. Series C US$288M (Sep 2020, led by SoftBank Vision Fund 2). Major pre-IPO holders included Tencent (13.7%), Sequoia China (8.3%) and 5Y Capital (7.9%) [local].
• Listed: HKEX (2228.HK), June 2024 under Chapter 18C (specialist technology) — the first AI drug-discovery company to list in Hong Kong. (Earlier versions of this page said Nov 2023; corrected.)
• Post-IPO capital: roughly RMB 7.6B raised within about a year of listing through three placings plus a HK$2.87B convertible bond; cash about RMB 7B [local].
• FY2025: revenue RMB 803M (+201%), first reported profit; but ~45% of revenue was a one-off DoveTree upfront (US$51M, on an end-to-end collaboration with total potential value up to ~US$5.99B) and ~RMB 0.5B fair-value gains — ex-items, operating loss ≈ RMB 0.4B [local]. Robotics-solution revenue ≈ RMB 265M (+63%).
• 2026H1 (reported 2026-07-24): revenue ≈ RMB 394M (−24% YoY on a high DoveTree base; ex-upfront growth ≈ +65–74%); AI4S intelligent-solutions revenue > RMB 180M (+120–136%), ≈49% of revenue; net loss to shareholders ≈ RMB 252M; R&D expense +50%+, directed at autonomous labs, agent systems and pipeline [gelonghui 2026-10-12].
• Revenue model: drug-discovery services + licensing/milestones + lab-automation solutions; recurring profitability not yet demonstrated.

6. People & Relationships

• Founders: three MIT physicists — 温书豪 (Shuhao Wen), 马健 (Jian Ma), 赖力鹏 (Lipeng Lai).
• Partners: Pfizer (early); Eli Lilly — AI + robotics collaboration announced 2023-05-30 to de novo design candidates for an undisclosed target, worth up to US$250M in upfront and milestone payments (upfront/milestone split not disclosed) [BioSpace; Yicai Global, 2026-10-14]; DoveTree (2025, end-to-end collaboration) [local].
• Peers: insilico-medicine, isomorphic-labs, Schrödinger, dp-technology.